Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860565 | 1.00 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL3922203 | 0.87 | MAPT (0.60) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL21444471 | 0.87 | MAPT (0.60) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL17571472 | 0.81 | MAPT (0.53) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL14831492 | 0.81 | MAPT (0.53) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL15077290 | 0.81 | MAPT (0.53) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL30935134 | 0.79 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL18474705 | 0.79 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL17555444 | 0.79 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL545466 | 0.79 | MAPT (0.47) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-117715897-A | Compounds and their use as CD38 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | MAPT 2724/4885KEAP1 2579/4885NFE2L2 2671/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | MAPT 2981/4885KEAP1 1439/4885NFE2L2 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.